This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Proteintech Group
product type :
antibody
product name :
MCL1
catalog :
16225-1-AP
quantity :
150UL
price :
299 USD
clonality :
polyclonal
host :
domestic rabbit
conjugate :
nonconjugated
reactivity :
human
application :
western blot, ELISA, immunohistochemistry, immunocytochemistry, immunoprecipitation
citations: 47
Published Application/Species/Sample/DilutionReference
  • immunoprecipitation; human; loading ...; fig s10b
  • western blot; human; loading ...; fig s10e
Li X, Song N, Liu L, Liu X, Ding X, Song X, et al. USP9X regulates centrosome duplication and promotes breast carcinogenesis. Nat Commun. 2017;8:14866 pubmed publisher
Li Y, Wu L, Zeng L, Zhang Z, Wang W, Zhang C, et al. ApoC1 promotes the metastasis of clear cell renal cell carcinoma via activation of STAT3. Oncogene. 2020;: pubmed publisher
Yan X, Yang C, Hu W, Chen T, Wang Q, Pan F, et al. Knockdown of KRT17 decreases osteosarcoma cell proliferation and the Warburg effect via the AKT/mTOR/HIF1α pathway. Oncol Rep. 2020;44:103-114 pubmed publisher
Hu X, Xia M, Wang J, Yu H, Chai J, Zhang Z, et al. Dual PI3K/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy. Biomed Pharmacother. 2020;129:110397 pubmed publisher
Liu Y, Tsai J, Weng Y, Hsu F. Regorafenib suppresses epidermal growth factor receptor signaling-modulated progression of colorectal cancer. Biomed Pharmacother. 2020;128:110319 pubmed publisher
Hu C, Xia H, Bai S, Zhao J, Edwards H, Li X, et al. CUDC-907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action. J Cell Mol Med. 2020;: pubmed publisher
Su Q, Wang J, Liu F, Zhang Y. Blocking Parkin/PINK1-mediated mitophagy sensitizes hepatocellular carcinoma cells to sanguinarine-induced mitochondrial apoptosis. Toxicol In Vitro. 2020;66:104840 pubmed publisher
Li X, Su Y, Hege K, Madlambayan G, Edwards H, Knight T, et al. The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia. Haematologica. 2020;: pubmed publisher
He T, Ji W, Zhang J, Lu J, Liu X. ALG-2 couples T cell activation and apoptosis by regulating proteasome activity and influencing MCL1 stability. Cell Death Dis. 2020;11:5 pubmed publisher
Carter R, Milani M, Butterworth M, Alotibi A, Harper N, Yedida G, et al. Exploring the potential of BH3 mimetic therapy in squamous cell carcinoma of the head and neck. Cell Death Dis. 2019;10:912 pubmed publisher
Chen P, Wang B, Mo Q, Wu P, Fang Y, Tian Y, et al. The LIV-1-GRPEL1 axis adjusts cell fate during anti-mitotic agent-damaged mitosis. EBioMedicine. 2019;49:26-39 pubmed publisher
Wu L, Lin Y, FENG J, Qi Y, Wang X, Lin Q, et al. The deubiquitinating enzyme OTUD1 antagonizes BH3-mimetic inhibitor induced cell death through regulating the stability of the MCL1 protein. Cancer Cell Int. 2019;19:222 pubmed publisher
Kumaran Satyanarayanan S, El Kebir D, Soboh S, Butenko S, Sekheri M, Saadi J, et al. IFN-β is a macrophage-derived effector cytokine facilitating the resolution of bacterial inflammation. Nat Commun. 2019;10:3471 pubmed publisher
Ma J, Zhao S, Qiao X, Knight T, Edwards H, Polin L, et al. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia. Clin Cancer Res. 2019;: pubmed publisher
Liu F, Knight T, Su Y, Edwards H, Wang G, Wang Y, et al. Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo. Target Oncol. 2019;: pubmed publisher
Liu Y, Wang H, Liu N, Du J, Lan X, Qi X, et al. Oxymatrine protects neonatal rat against hypoxic-ischemic brain damage via PI3K/Akt/GSK3β pathway. Life Sci. 2019;: pubmed publisher
Xie L, Dai H, Li M, Yang W, Yu G, Wang X, et al. MARCH1 encourages tumour progression of hepatocellular carcinoma via regulation of PI3K-AKT-β-catenin pathways. J Cell Mol Med. 2019;23:3386-3401 pubmed publisher
Xie L, Li M, Liu D, Wang X, Wang P, Dai H, et al. Secalonic Acid-F, a Novel Mycotoxin, Represses the Progression of Hepatocellular Carcinoma via MARCH1 Regulation of the PI3K/AKT/β-catenin Signaling Pathway. Molecules. 2019;24: pubmed publisher
Wang Y, Zhang J, Li J, Gui R, Nie X, Huang R. CircRNA_014511 affects the radiosensitivity of bone marrow mesenchymal stem cells by binding to miR-29b-2-5p. Bosn J Basic Med Sci. 2019;19:155-163 pubmed publisher
Chen L, Liu L, Xie Z, Wang F, Zhu L, Zhang C, et al. Protein kinase RNA-like ER kinase/eukaryotic translation initiation factor 2α pathway attenuates tumor necrosis factor alpha-induced apoptosis in nucleus pulposus cells by activating autophagy. J Cell Physiol. 2019;234:11631-11645 pubmed publisher
Liu Y, Wang S, Xu Q, Yuan H, Guo Y, Wang Q, et al. Acetyl-11-keto-β-boswellic acid suppresses docetaxel-resistant prostate cancer cells in vitro and in vivo by blocking Akt and Stat3 signaling, thus suppressing chemoresistant stem cell-like properties. Acta Pharmacol Sin. 2019;40:689-698 pubmed publisher
Wang X, Liu W, Wang P, Li S. RNA interference of long noncoding RNA HOTAIR suppresses autophagy and promotes apoptosis and sensitivity to cisplatin in oral squamous cell carcinoma. J Oral Pathol Med. 2018;47:930-937 pubmed publisher
Xie L, Zeng Y, Dai Z, He W, Ke H, Lin Q, et al. Chemical and genetic inhibition of STAT3 sensitizes hepatocellular carcinoma cells to sorafenib induced cell death. Int J Biol Sci. 2018;14:577-585 pubmed publisher
Chen L, Cheng C, Gao H, Zhan L, Wang F, Qu C, et al. Natural Compound Methyl Protodioscin Suppresses Proliferation and Inhibits Glycolysis in Pancreatic Cancer. Evid Based Complement Alternat Med. 2018;2018:7343090 pubmed publisher
Rasmussen M, Kline L, Park K, Ortolano N, Romero Morales A, Anthony C, et al. A Non-apoptotic Function of MCL-1 in Promoting Pluripotency and Modulating Mitochondrial Dynamics in Stem Cells. Stem Cell Reports. 2018;10:684-692 pubmed publisher
Campbell K, Dhayade S, Ferrari N, Sims A, Johnson E, Mason S, et al. MCL-1 is a prognostic indicator and drug target in breast cancer. Cell Death Dis. 2018;9:19 pubmed publisher
Su Y, Li X, Ma J, Zhao J, Liu S, Wang G, et al. Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo. Biochem Pharmacol. 2018;148:13-26 pubmed publisher
Huang R, Liu H, Chen Y, He Y, Kang Q, Tu S, et al. EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway. Oncol Rep. 2018;39:119-128 pubmed publisher
Yin S, Du W, Wang F, Han B, Cui Y, Yang D, et al. MicroRNA-326 sensitizes human glioblastoma cells to curcumin via the SHH/GLI1 signaling pathway. Cancer Biol Ther. 2018;19:260-270 pubmed publisher
Zhao Y, He J, Li J, Peng X, Wang X, Dong Z, et al. Demethylzeylasteral inhibits cell proliferation and induces apoptosis through suppressing MCL1 in melanoma cells. Cell Death Dis. 2017;8:e3133 pubmed publisher
Ning C, Liang M, Liu S, Wang G, Edwards H, Xia Y, et al. Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer. Oncotarget. 2017;8:44295-44311 pubmed publisher
Lu L, Zhang S, Li C, Zhou C, Li D, Liu P, et al. Cryptotanshinone inhibits human glioma cell proliferation in vitro and in vivo through SHP-2-dependent inhibition of STAT3 activation. Cell Death Dis. 2017;8:e2767 pubmed publisher
Gao C, Sun R, Xie Y, Jiang A, Lin M, Li M, et al. The soy-derived peptide Vglycin inhibits the growth of colon cancer cells in vitro and in vivo. Exp Biol Med (Maywood). 2017;242:1034-1043 pubmed publisher
Zheng M, Xu H, Liao X, Chen C, Zhang A, Lu W, et al. Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma. Oncotarget. 2017;8:29771-29784 pubmed publisher
Li C, Miao R, Liu S, Wan Y, Zhang S, Deng Y, et al. Down-regulation of miR-146b-5p by long noncoding RNA MALAT1 in hepatocellular carcinoma promotes cancer growth and metastasis. Oncotarget. 2017;8:28683-28695 pubmed publisher
Wei W, Sun Z, Shen C, Song H, Zhang X, Qiu Z, et al. Obatoclax and LY3009120 Efficiently Overcome Vemurafenib Resistance in Differentiated Thyroid Cancer. Theranostics. 2017;7:987-1001 pubmed publisher
Huang W, Ren C, Huang G, Liu J, Liu W, Wang L, et al. Inhibition of store-operated Ca2+ entry counteracts the apoptosis of nasopharyngeal carcinoma cells induced by sodium butyrate. Oncol Lett. 2017;13:921-929 pubmed publisher
Yao S, Xu F, Chen Y, Ge Y, Zhang F, Huang H, et al. Fbw7 regulates apoptosis in activated B-cell like diffuse large B-cell lymphoma by targeting Stat3 for ubiquitylation and degradation. J Exp Clin Cancer Res. 2017;36:10 pubmed publisher
Feng T, Cao W, Shen W, Zhang L, Gu X, Guo Y, et al. Arctigenin inhibits STAT3 and exhibits anticancer potential in human triple-negative breast cancer therapy. Oncotarget. 2017;8:329-344 pubmed publisher
Wei W, Shen C, Song H, Qiu Z, Luo Q. Propranolol sensitizes thyroid cancer cells to cytotoxic effect of vemurafenib. Oncol Rep. 2016;36:1576-84 pubmed publisher
Wang S, Zhang W, Wu X, Weng M, Zhang M, Cai Q, et al. The lncRNA MALAT1 functions as a competing endogenous RNA to regulate MCL-1 expression by sponging miR-363-3p in gallbladder cancer. J Cell Mol Med. 2016;20:2299-2308 pubmed publisher
Wang Z, Tang F, Hu P, Wang Y, Gong J, Sun S, et al. HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma. Oncol Rep. 2016;36:589-97 pubmed publisher
McCracken J, Kinkead L, McCaffrey R, Allen L. Francisella tularensis Modulates a Distinct Subset of Regulatory Factors and Sustains Mitochondrial Integrity to Impair Human Neutrophil Apoptosis. J Innate Immun. 2016;8:299-313 pubmed publisher
Zhao S, Li H, Jiang C, Ma T, Wu C, Huo Q, et al. 17-Demethoxy-reblastatin, an Hsp90 inhibitor, induces mitochondria-mediated apoptosis through downregulation of Mcl-1 in human hepatocellular carcinoma cells. J Bioenerg Biomembr. 2015;47:373-81 pubmed publisher
Huang W, Liu J, Feng X, Chen H, Zeng L, Huang G, et al. DLC-1 induces mitochondrial apoptosis and epithelial mesenchymal transition arrest in nasopharyngeal carcinoma by targeting EGFR/Akt/NF-κB pathway. Med Oncol. 2015;32:115 pubmed publisher
Dai B, Wang W, Liu R, Wang H, Zhang Y. Novel taspine derivative 12k inhibits cell growth and induces apoptosis in lung cell carcinoma. Biomed Pharmacother. 2015;70:227-33 pubmed publisher
Xiang M, Su H, Hong Z, Yang T, Shu G. Chemical composition of total flavonoids from Polygonum amplexicaule and their pro-apoptotic effect on hepatocellular carcinoma cells: Potential roles of suppressing STAT3 signaling. Food Chem Toxicol. 2015;80:62-71 pubmed publisher
product information
CatalogNo :
16225-1-AP
AntigenName :
MCL1
Package :
150UL
Price :
299 USD
Exsists20ul :
20ul trial size available
FullName :
myeloid cell leukemia sequence 1 (BCL2-related)
Immunogen :
Recombinant Protein
Species :
human, mouse, rat
Host :
Rabbit
IsConjugated :
Unconjugated
AntigenSpecies :
human
Application :
WB, IP, IHC, IF, ELISA
Clonlity :
Polyclonal
IsoType :
IgG
Synonyms :
EAT, Mcl 1, Mcl 1l, Mcl 1s Delta TM, MCL1, mcl1/EAT, MCL1L, MCL1S, TM
PrimaryOrSecondary :
Primary
AntibodyBuffer :
PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
GenBankNo :
BC107735
Category :
Apoptosis;Binding Proteins;Cell Cycle;Cytoskeleton/Scaffold Proteins;Development;Disease Related;IVD;Membrane Proteins;Metabolism;Oncogene(s) and Tumor Suppressor(s);Stem Cells;
PurifyMethod :
Antigen affinity purification
NewAb :
False
IsSellable :
True
Feature :
siRNA
AppTiter :
IHC 1:200 ; IP 1:1000 ; WB 1:2000 ;
company information
Proteintech Group
2201 W. Campbell Park Dr. STE12
Chicago, IL 60612
Proteintech@ptglab.com
https://www.ptglab.com
1-312-455-8498
headquarters: USA
At Proteintech, we produce every single antibody we sell; we do not rely on or supply to any other antibody providers: our products are unique and we are 100% accountable for each one. We realize this accountability by validating in-house, providing extensive technical support and guaranteeing your success: in addition to helping you troubleshoot your experiment, we will offer you a full cash refund if you are in any way dissatisfied. We can guarantee satisfaction because we have confidence in our products, confidence cultivated by the science behind our antibodies: we make them using as much of the native protein as possible, and purifying them using affinity purification with the original antigen. We carry out antibody production over a 102-day period, which allows for better antigen fitting to MHC molecules and affinity maturation in the host. This approach results in higher affinity antibodies with greater sensitivity, which you can use in any application and in multiple species.
You can only buy Proteintech antibodies directly from Proteintech or via one of its approved distributors — when you receive your antibody and see the Proteintech logo on the vial, know that you hold something that is truly unique.